Tharimmune (THAR) announced the expansion of its product pipeline with HS1940, a dual-target multispecific biologic engineered to bind to both ...

DelveInsight's "TAGRISSO Market Size, Forecast, and Market Insight Report" highlights the details around TAGRISSO, a kinase ...

Operator Welcome to BioNTech's fourth quarter and full year 2024 earnings call. I would like to hand the call over to Michael ...

Akeso begins patient enrolment in phase I trial of AK138 D1 for the treatment of advanced malignancies in Australia: Hong Kong Saturday, March 1, 2025, 12:00 Hrs [IST] Akeso, Inc.

Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the treatment of advanced malignancies in Australia. AK138D1,  a self-developed and ...

We have started exploring combinations of BNT327 with four ADCs directed against TROP2, HER2, HER3, B7H3 from our partnerships with Duality and MediLink and informed by a robust database of single ...

TAGRISSO has become a standard treatment due to its strong efficacy in both first-line and adjuvant settings. The growing prevalence of EGFR mutations, a rise in lung cancer diagnoses, and broader ...

HER2-targeted therapies, and chemotherapy. Injectable AK138D1 is a HER3-targeted antibody-drug conjugate (ADC), with a fully humanized anti-HER3 IgG1 antibody, patritumab. It is conjugated to the ...

In addition to HS1940, Tharimmune is developing multispecific antibodies targeting HER2 and HER3, other validated cancer growth drivers. Leveraging the EpiClick platform, the company aims to ...